Patents by Inventor Alexander Ljubimov

Alexander Ljubimov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190321494
    Abstract: Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 24, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Keith L. Black, Julia Ljubimova, Alexander Ljubimov, Eggehard Holler
  • Patent number: 10383958
    Abstract: Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: August 20, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Keith L. Black, Julia Ljubimova, Alexander Ljubimov, Eggehard Holler
  • Publication number: 20190060479
    Abstract: Nanoimmunoconjugates including a polymalic acid-based molecular scaffold, targeting ligands, anti-tumor immune response stimulators and anti-cancer agents are provided. Methods for treating cancer in a subject by administering the nanoimmunoconjugates that provide both systemic and local immune responses and synergistic anticancer effect are described.
    Type: Application
    Filed: March 3, 2017
    Publication date: February 28, 2019
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Julia Y. LJUBIMOVA, Keith L. BLACK, Eggehard HOLLER, Alexander LJUBIMOV, Hui DING
  • Publication number: 20120258049
    Abstract: Nanoconjugates that include a polymalic-based molecular scaffold with one or more imaging moiety and one or more targeting modules attached to the scaffold are provided. Methods of targeting a diseased cell or a diseased tissue in a subject by administering the nanoconjugate are described. Methods of synthesizing the nanoconjugate are also provided.
    Type: Application
    Filed: April 6, 2012
    Publication date: October 11, 2012
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Keith L. Black, Julia Ljubimova, Alexander Ljubimov, Eggehard Holler
  • Publication number: 20070105797
    Abstract: Using gene array technology, we observed that an increase of the ?4 chain-containing Laminin-8 correlated with poor prognosis for patients with brain gliomas. We established that inhibition of Laminin-8 expression by a new generation of highly specific and stable antisense oligonucleotides (Morpholino™) against chains of Laminin-8 could slow or stop the spread of glioma. This was demonstrated in an in vitro model using human glioblastoma multiforme cell lines M059K and U-87MG co-cultured with normal human brain microvascular endothelial cells (HBMVEC). Using Western blot analysis and immunohistochemistry, we con-firmed that antisense treatment effectively blocked laminin-8 protein synthesis. Antisense oligonucleotides against both ?4 and ?1 chains of laminin-8 blocked significantly the invasion of co-cultures through Matrigel.
    Type: Application
    Filed: September 13, 2004
    Publication date: May 10, 2007
    Applicant: Cedars-Sinai Medical Center
    Inventors: Julia Ljubimova, Alexander Ljubimov, Keith Black
  • Publication number: 20040121968
    Abstract: A method of inhibiting angiogenesis in a mammal is disclosed, which employs a pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 (also known as casein kinase II) enzymatic activity, such as emodin, aloe-emodin, 5,6-dichloro-1-&bgr;-D-ribofuranosylbenzimidazole (DRB), and 4,5,6,7-tetrabromobenzotriazole (TBB). Also disclosed is a use of a selective inhibitor of protein kinase CK2 enzymatic activity in the manufacture of a medicament for inhibiting angiogenesis. An in vitro method of screening a potential antiangiogenic agent is also disclosed. A kit for the treatment of a disease by inhibiting angiogenesis is disclosed that contains the pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 enzymatic activity.
    Type: Application
    Filed: December 23, 2002
    Publication date: June 24, 2004
    Inventors: Alexander Ljubimov, Raquel Castellon, Maria Grant